Recent Advances in Adipokines (3nd Edition)

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: 31 October 2026 | Viewed by 4014

Special Issue Editor

Special Issue Information

Dear Colleagues,

This Special Issue, “Recent Advances in Adipokines (3nd Edition)”, will cover a selection of original research articles and review articles related to adipokines.

Soluble proteins produced from adipose tissue are referred to as adipokines irrespective of their cellular source. White fat tissue is organized into different depots in the body. Subcutaneous and visceral adipose tissues are the best-studied compartments. Adipose tissues are also localized around organs, such as the heart and kidneys. Brown adipose tissue differs greatly from white fat and has its own set of secreted hormones, the so-called “brown adipokines”.

To date, more than 500 adipokines have been described, and most of them are associated with overweight/obesity. Whilst levels of various adipokines are increased in the serum of the obese, others decline. Associations between adipokines and cardiovascular diseases, insulin resistance, different types of cancers, and many more diseases have been identified. Further research has focused on the role of these proteins in immune responses, in autoimmune diseases, and as antimicrobial peptides. Adipokines in serum, plasma, saliva, or urine may emerge as diagnostic and/or prognostic biomarkers for various diseases.

Adipokine receptors are mostly not well characterized. Cell type and tissue expression, regulation using different metabolites, and signalling pathways have to be studied in more detail. Adipokine receptor agonists/antagonists may finally become new therapeutic targets.

Prof. Dr. Christa Büchler
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adiponectin
  • receptor
  • agonist
  • biomarker
  • inflammation
  • cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2110 KB  
Article
Age-Dependent Systemic Regulation of C1q/TNF-Related Protein 3 and Progranulin in Patients with Cystic Fibrosis: Biomarkers or Therapeutic Targets?
by Andreas Schmid, Miriam Arians, Caroline Gunchick, Andreas Schäffler, Martin Roderfeld and Elke Roeb
Biomedicines 2026, 14(3), 706; https://doi.org/10.3390/biomedicines14030706 - 18 Mar 2026
Viewed by 496
Abstract
Background/Objectives: C1q/TNF-related protein 3 (CTRP3), progranulin (PGRN), and chemerin are adipokines that participate in systemic inflammation. This study systematically examined adipokine levels in cystic fibrosis patients of different ages to evaluate their role in inflammatory, metabolic, and hepatic processes. Thirty-seven pediatric and [...] Read more.
Background/Objectives: C1q/TNF-related protein 3 (CTRP3), progranulin (PGRN), and chemerin are adipokines that participate in systemic inflammation. This study systematically examined adipokine levels in cystic fibrosis patients of different ages to evaluate their role in inflammatory, metabolic, and hepatic processes. Thirty-seven pediatric and thirty-three adult CF patients were enrolled to assess the potential of these adipokines as biomarkers. Methods: Anthropometric and physiological data, pulmonary function (forced expiratory volume, FEV1; vital capacity, VC), and liver fibrosis score FIB-4 were assessed. Liver stiffness was measured by transient elastography. Serum samples from 40 healthy adult volunteers served as the control group. Serum concentrations of chemerin, CTRP3, and PGRN were quantified by enzyme-linked immunosorbent assay (ELISA). Results: Compared with healthy controls, adults with CF had markedly lower circulating CTRP3 levels, whereas PGRN concentrations were significantly higher. Among CF patients, both CTRP3 and PGRN were higher in the pediatric group than in adults, while chemerin did not vary with age. The presence of cystic fibrosis-related liver disease (CFLD) did not significantly alter adipokine levels relative to CF patients without liver disease. Receiver operator characteristic (ROC) analysis showed that circulating PGRN could reliably differentiate CF patients from controls; none of the three adipokines predicted the presence of CFLD. CTRP3 and PGRN were inversely correlated with age, BMI, and pulmonary function. Conclusions: Overall, our data support systemic PGRN as a potential biomarker for CF and indicate an age-dependent regulation of circulating CTRP3 and PGRN. Both proteins were inversely associated with BMI, inflammatory markers, liver fibrosis, and pulmonary capacity. Full article
(This article belongs to the Special Issue Recent Advances in Adipokines (3nd Edition))
Show Figures

Figure 1

16 pages, 1733 KB  
Article
Resistin as Modulator of Functional Activity of Phagocytes in Colostrum and Blood of Overweight and Obese Mothers
by Carla Roberta Silva Souza Antônio, Elisia Possidônea Pereira, Danielle Cristina Honorio França, Patricia Gelli Feres de Marchi, Emanuelle Carolina Honorio França, Anibal Monteiro de Magalhães Neto, Elton Brito Ribeiro, Danny Laura Gomes Fagundes-Triches, Adenilda Cristina Honorio-França and Eduardo Luzía França
Biomedicines 2025, 13(11), 2815; https://doi.org/10.3390/biomedicines13112815 - 18 Nov 2025
Viewed by 740
Abstract
Background/Objectives: Resistin is an adipokine involved in obesity pathogenesis, but its effects on blood and colostrum immune cells from obese mothers remain unclear. This study evaluated the functional activity of phagocytes modulated by resistin in blood and colostrum from overweight and obese [...] Read more.
Background/Objectives: Resistin is an adipokine involved in obesity pathogenesis, but its effects on blood and colostrum immune cells from obese mothers remain unclear. This study evaluated the functional activity of phagocytes modulated by resistin in blood and colostrum from overweight and obese mothers. Methods: An observational study was conducted with 82 postpartum women divided according to pregestational BMI into control, overweight, and obese groups. Blood and colostrum samples were collected to determine resistin levels and assess the functional activity of mononuclear (MN) cells. Results: Plasma resistin levels were higher in overweight mothers, whereas colostrum levels were lower in obese mothers. Resistin treatment enhanced superoxide release in both colostrum and blood phagocytes, independent of maternal weight status. In the presence of enteropathogenic Escherichia coli (EPEC), resistin-treated phagocytes from both colostrum and maternal blood showed increased superoxide production. In blood cells from overweight mothers, resistin reduced superoxide dismutase (SOD) concentration, while in colostrum, the highest SOD levels were observed in cultures of resistin-treated cells from mothers with altered weight, regardless of weight status. Blood and colostrum cells treated with resistin increased phagocytosis rates. In colostrum, resistin-treated cells from eutrophic mothers showed high microbicidal indices, whereas cells from mothers with altered weight showed reduced microbicidal indices. In colostrum cells, adipokine levels were reduced in the obesity group. Conclusions: Resistin modulates oxidative metabolism and the functional activity of blood and colostrum phagocytes across all maternal weight statuses, suggesting a possible role for resistin in the maternal immune response associated with obesity. Full article
(This article belongs to the Special Issue Recent Advances in Adipokines (3nd Edition))
Show Figures

Figure 1

Review

Jump to: Research

24 pages, 2766 KB  
Review
Anti-Angiogenic Features of Endostatin in Obesity, Liver Fibrosis, and Hepatocellular Carcinoma
by Thomas Grewal and Christa Buechler
Biomedicines 2026, 14(3), 734; https://doi.org/10.3390/biomedicines14030734 - 23 Mar 2026
Viewed by 903
Abstract
Background/objectives: Endostatin is a cleavage product of collagen XVIII and a potent anti-angiogenic factor. Angiogenesis is essential for adipose tissue growth and contributes to liver fibrosis and cancer, suggesting a potential therapeutic role for endostatin in obesity, chronic liver diseases, and hepatocellular [...] Read more.
Background/objectives: Endostatin is a cleavage product of collagen XVIII and a potent anti-angiogenic factor. Angiogenesis is essential for adipose tissue growth and contributes to liver fibrosis and cancer, suggesting a potential therapeutic role for endostatin in obesity, chronic liver diseases, and hepatocellular carcinoma (HCC). This review article summarises published data on the role and expression of endostatin in obesity, liver injury, and HCC. Methods: PubMed and Google databases were searched using the terms “endostatin and liver”, “endostatin and HCC”, “endostatin and obesity”, and “endostatin and adipose”. Studies published in peer-reviewed journals relevant to this review were considered and reviewed for valuable insights. Results: Endostatin is much more than an inhibitor of angiogenesis; it exerts direct effects on adipocytes and myofibroblasts. Endostatin inhibits adipose tissue growth, and studies using Endostar—a modified form of endostatin approved in China for treating lung cancer—have demonstrated its protective effect in liver fibrosis. However, other studies have shown that endostatin activates hepatic stellate cells, indicating a role in tissue regeneration. Most research on endostatin has focused on cancer, and animal and human studies have shown the benefits of Endostar therapy in HCC. Conclusions: Endostar is a promising treatment for HCC and may also become an attractive drug for liver fibrosis. Hence, angiostatic therapy is not without risks and may only be suitable for selected patients. Full article
(This article belongs to the Special Issue Recent Advances in Adipokines (3nd Edition))
Show Figures

Graphical abstract

17 pages, 1049 KB  
Review
Adipose-Specific Cytokines as Modulators of Reproductive Activity
by Marcelo Martinez-Barbitta, Andrea Biagini, Egidia Costanzi, Margherita Maranesi, Juan García-Díez, Cristina Saraiva, Beniamino Cenci Goga and Massimo Zerani
Biomedicines 2025, 13(12), 3067; https://doi.org/10.3390/biomedicines13123067 - 12 Dec 2025
Viewed by 932
Abstract
Adipose tissue is characterized by specialized lipid handling cells called adipocytes, which function as the primary energy reservoir. Like many other cell types, adipocytes have highly plastic properties, such as the conversion of white adipocytes into brown or beige adipocytes, which produce heat, [...] Read more.
Adipose tissue is characterized by specialized lipid handling cells called adipocytes, which function as the primary energy reservoir. Like many other cell types, adipocytes have highly plastic properties, such as the conversion of white adipocytes into brown or beige adipocytes, which produce heat, and pink adipocytes into mammary cells synthesizing and secreting milk. Highly specialized adipose tissue depots are present in various species, such as male orangutans with prominent fat-filled facial flanges indicating hierarchical status, or cetaceans with the melon, a specialized adipose tissue for echolocation. Adipose tissue is now considered a true endocrine organ that regulates various physiological mechanisms through the hormonal secretion of adipokines, which modulate systemic metabolism and physiological processes. In particular, the role of adipokines in the control of the reproductive axis and their participation in the regulation of fertility have been widely reported. This review summarizes the current state of research on the effects of adipose-specific cytokines on the male and female reproductive systems. Full article
(This article belongs to the Special Issue Recent Advances in Adipokines (3nd Edition))
Show Figures

Figure 1

Back to TopTop